These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 8430863)
21. Vasodilatory effects of C-type natriuretic peptide on forearm resistance vessels are distinct from those of atrial natriuretic peptide in chronic heart failure. Nakamura M; Arakawa N; Yoshida H; Makita S; Hiramori K Circulation; 1994 Sep; 90(3):1210-4. PubMed ID: 8087930 [TBL] [Abstract][Full Text] [Related]
22. CNP, but not ANP or BNP, relax human isolated subcutaneous resistance arteries by an action involving cyclic GMP and BKCa channels. Garcha RS; Hughes AD J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7(2):87-91. PubMed ID: 17083062 [TBL] [Abstract][Full Text] [Related]
23. Effects of exogenous and endogenous natriuretic peptides on forearm vascular function in chronic heart failure. Schmitt M; Gunaruwan P; Payne N; Taylor J; Lee L; Broadley AJ; Nightingale AK; Cockcroft JR; Struthers AD; Tyberg JV; Frenneaux MP Arterioscler Thromb Vasc Biol; 2004 May; 24(5):911-7. PubMed ID: 15001459 [TBL] [Abstract][Full Text] [Related]
24. C-type natriuretic peptide mediates the hypothalamic actions of the natriuretic peptides to inhibit luteinizing hormone secretion. Samson WK; Huang FL; Fulton RJ Endocrinology; 1993 Feb; 132(2):504-9. PubMed ID: 8425472 [TBL] [Abstract][Full Text] [Related]
25. C-type natriuretic peptide increases myocardial contractility and sinus rate mediated by guanylyl cyclase-linked natriuretic peptide receptors in isolated, blood-perfused dog heart preparations. Hirose M; Furukawa Y; Kurogouchi F; Nakajima K; Miyashita Y; Chiba S J Pharmacol Exp Ther; 1998 Jul; 286(1):70-6. PubMed ID: 9655843 [TBL] [Abstract][Full Text] [Related]
26. C-type natriuretic peptide-mediated coronary vasodilation: role of the coronary nitric oxide and particulate guanylate cyclase systems. Wright RS; Wei CM; Kim CH; Kinoshita M; Matsuda Y; Aarhus LL; Burnett JC; Miller WL J Am Coll Cardiol; 1996 Oct; 28(4):1031-8. PubMed ID: 8837586 [TBL] [Abstract][Full Text] [Related]
27. Role of natriuretic peptide clearance receptor in in vivo control of C-type natriuretic peptide. Brandt RR; Heublein DM; Aarhus LL; Lewicki JA; Burnett JC Am J Physiol; 1995 Jul; 269(1 Pt 2):H326-31. PubMed ID: 7631865 [TBL] [Abstract][Full Text] [Related]
28. Cyclic guanosine monophosphate production in the pituitary: stimulation by C-type natriuretic peptide and inhibition by gonadotropin-releasing hormone in alpha T3-1 cells. McArdle CA; Poch A; Käppler K Endocrinology; 1993 May; 132(5):2065-72. PubMed ID: 7682940 [TBL] [Abstract][Full Text] [Related]
29. Diverging vasorelaxing effects of C-type natriuretic peptide in renal resistance arteries and aortas of GC-A-deficient mice. Steinmetz M; Potthast R; Sabrane K; Kuhn M Regul Pept; 2004 Jun; 119(1-2):31-7. PubMed ID: 15093694 [TBL] [Abstract][Full Text] [Related]
30. Natriuretic peptides as regulatory mediators of secretory activity in the digestive system. Sabbatini ME Regul Pept; 2009 Apr; 154(1-3):5-15. PubMed ID: 19233231 [TBL] [Abstract][Full Text] [Related]
31. Activation of myocardial and renal natriuretic peptides during acute intravascular volume overload in dogs: functional cardiorenal responses to receptor antagonism. Borgeson DD; Stevens TL; Heublein DM; Matsuda Y; Burnett JC Clin Sci (Lond); 1998 Aug; 95(2):195-202. PubMed ID: 9680502 [TBL] [Abstract][Full Text] [Related]
32. Differential sensitivity to endothelin in canine arteries and veins. Miller VM; Komori K; Burnett JC; Vanhoutte PM Am J Physiol; 1989 Oct; 257(4 Pt 2):H1127-31. PubMed ID: 2679147 [TBL] [Abstract][Full Text] [Related]
33. CNP-22 stimulates, rather than inhibits, water drinking in the rat: evidence for a unique biological action of the C-type natriuretic peptides. Samson WK; Skala KD; Huang FL Brain Res; 1991 Dec; 568(1-2):285-8. PubMed ID: 1839968 [TBL] [Abstract][Full Text] [Related]
34. Vascular actions of C-type natriuretic peptide in isolated porcine coronary arteries and coronary vascular smooth muscle cells. Wei CM; Hu S; Miller VM; Burnett JC Biochem Biophys Res Commun; 1994 Nov; 205(1):765-71. PubMed ID: 7999110 [TBL] [Abstract][Full Text] [Related]
35. C-type natriuretic peptide in chronic renal failure and its action in humans. Igaki T; Itoh H; Suga S; Hama N; Ogawa Y; Komatsu Y; Mukoyama M; Sugawara A; Yoshimasa T; Tanaka I; Nakao K Kidney Int Suppl; 1996 Jun; 55():S144-7. PubMed ID: 8743538 [TBL] [Abstract][Full Text] [Related]
37. Central action of C-type natriuretic peptide on vasopressin secretion in conscious rats. Shirakami G; Itoh H; Suga S; Komatsu Y; Hama N; Mori K; Nakao K Neurosci Lett; 1993 Sep; 159(1-2):25-8. PubMed ID: 8264972 [TBL] [Abstract][Full Text] [Related]
38. Action of atrial natriuretic peptide (ANP) on dog cerebral arteries: evidence that neurogenic relaxation is not mediated by release of ANP. Okamura T; Inoue S; Toda N Br J Pharmacol; 1989 Aug; 97(4):1258-64. PubMed ID: 2529017 [TBL] [Abstract][Full Text] [Related]
39. The natriuretic peptide system in the brain: implications in the central control of cardiovascular and neuroendocrine functions. Imura H; Nakao K; Itoh H Front Neuroendocrinol; 1992 Jul; 13(3):217-49. PubMed ID: 1334000 [TBL] [Abstract][Full Text] [Related]
40. Bioactivity and metabolism of C-type natriuretic peptide in normal man. Hunt PJ; Richards AM; Espiner EA; Nicholls MG; Yandle TG J Clin Endocrinol Metab; 1994 Jun; 78(6):1428-35. PubMed ID: 8200946 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]